JP2015502958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502958A5 JP2015502958A5 JP2014546103A JP2014546103A JP2015502958A5 JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5 JP 2014546103 A JP2014546103 A JP 2014546103A JP 2014546103 A JP2014546103 A JP 2014546103A JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- effective amount
- therapeutically effective
- pathway inhibitor
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091007472 MAP kinase family Proteins 0.000 claims 3
- 102000004331 Mitogen-Activated Protein Kinases Human genes 0.000 claims 3
- 108090000823 Mitogen-Activated Protein Kinases Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229940121396 Wnt pathway inhibitors Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Claims (2)
- ***促進因子活性化タンパク質キナーゼ(MAPK)経路阻害剤の治療的有効量と組み合わせてWnt経路阻害剤の治療的有効量を対象に投与する段階を含む、対象におけるがんを処置する方法。
- MAPK経路阻害剤の治療的有効量と組み合わせてWnt経路阻害剤の治療的有効量を対象に投与する段階を含む、対象における腫瘍成長を阻害する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161568844P | 2011-12-09 | 2011-12-09 | |
US61/568,844 | 2011-12-09 | ||
US201261698030P | 2012-09-07 | 2012-09-07 | |
US61/698,030 | 2012-09-07 | ||
PCT/US2012/068351 WO2013086260A2 (en) | 2011-12-09 | 2012-12-07 | Combination therapy for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015502958A JP2015502958A (ja) | 2015-01-29 |
JP2015502958A5 true JP2015502958A5 (ja) | 2016-02-04 |
Family
ID=48575059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014546103A Pending JP2015502958A (ja) | 2011-12-09 | 2012-12-07 | がんの処置のための併用療法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150132301A1 (ja) |
EP (1) | EP2788378A4 (ja) |
JP (1) | JP2015502958A (ja) |
WO (1) | WO2013086260A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6081995B2 (ja) | 2011-06-17 | 2017-02-15 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 癌の処置における治療抗体の標的としてのFrizzled2 |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
WO2015009851A1 (en) * | 2013-07-16 | 2015-01-22 | Icahn School Of Medicine At Mount Sinai | Methods of treating cancer in subjects afflicted with metabolic dysfunction |
KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
CN105829547A (zh) * | 2013-12-02 | 2016-08-03 | 昂科梅德制药有限公司 | 与Wnt途径抑制剂有关的预测性生物标记物的鉴别 |
WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
EP2975047A1 (en) * | 2014-07-18 | 2016-01-20 | Université de Lausanne | Wnt7a polypeptides and their use |
WO2017040666A2 (en) * | 2015-08-31 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
WO2018170485A1 (en) * | 2017-03-16 | 2018-09-20 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic and therapeutic methods for kras positive cancers |
CN107441045B (zh) * | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
CN117677398A (zh) * | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
US20230383360A1 (en) * | 2021-12-16 | 2023-11-30 | D2G Oncology, Inc. | Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL142481A0 (en) * | 2001-04-05 | 2002-03-10 | Yissum Res Dev Co | A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof |
JP5133071B2 (ja) * | 2006-02-09 | 2013-01-30 | 第一三共株式会社 | 抗癌医薬組成物 |
CA2662508A1 (en) * | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
US8063066B2 (en) * | 2007-03-19 | 2011-11-22 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
PE20090286A1 (es) * | 2007-05-11 | 2009-03-27 | Bayer Schering Pharma Ag | Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitogenos |
EP2164850B1 (en) * | 2007-06-12 | 2016-01-13 | Genentech, Inc. | N-substituted azaindoles and methods of use |
AR067562A1 (es) * | 2007-07-18 | 2009-10-14 | Novartis Ag | Compuestos heterociclicos inhibidores de kinasa |
CN103479604B (zh) * | 2007-07-30 | 2016-08-10 | 阿迪生物科学公司 | 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法 |
UA99731C2 (ru) * | 2007-07-30 | 2012-09-25 | Ардеа Биосайенсис, Инк | Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение |
US20100267626A1 (en) * | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
ES2456966T3 (es) * | 2007-11-12 | 2014-04-24 | Takeda Pharmaceutical Company Limited | Inhibidores de MAPK/ERK cinasa |
NZ592338A (en) * | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
JP5767122B2 (ja) * | 2009-03-11 | 2015-08-19 | アルデア バイオサイエンシズ,インコーポレイティド | 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬 |
US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
TWI535445B (zh) * | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
CN103038364A (zh) * | 2010-03-09 | 2013-04-10 | 达纳-法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
AU2011235904B2 (en) * | 2010-04-01 | 2015-10-08 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
US20120231965A1 (en) * | 2011-02-03 | 2012-09-13 | Prometheus Laboratories Inc. | Drug selection for colorectal cancer therapy using antibody-based arrays |
EA028821B9 (ru) * | 2011-02-07 | 2018-10-31 | Плексксикон, Инк. | Соединения и способы для модуляции киназ, а также показания к их применению |
-
2012
- 2012-12-07 US US14/362,991 patent/US20150132301A1/en not_active Abandoned
- 2012-12-07 EP EP12854925.0A patent/EP2788378A4/en not_active Withdrawn
- 2012-12-07 WO PCT/US2012/068351 patent/WO2013086260A2/en active Application Filing
- 2012-12-07 JP JP2014546103A patent/JP2015502958A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015502958A5 (ja) | ||
IL267609B (en) | Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases | |
HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
IL231591A0 (en) | Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
WO2015003360A3 (en) | Therapeutically active compounds and their methods of use | |
HK1201755A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
EP3065549A4 (en) | Methods for inhibiting tie2 kinase useful in the treatment of cancer | |
HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
PL3004108T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób | |
HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
ZA201607740B (en) | Treatment of the complications of chronic liver disease with caspase inhibitors | |
WO2015003355A3 (en) | Therapeutically active compounds and their methods of use | |
PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
FI2945642T3 (fi) | Tekijä 1 proteiini käytettäväksi sairauksien hoitoon tai ehkäisemiseen | |
HK1198128A1 (en) | Use of arctigenin in the preparation of medicament for the treatment of gastrointestinal ulcer diseases | |
HK1210412A1 (zh) | 鹽和糖的混合物在製備用於治療哺乳動物的***鬆弛綜合征或***乾燥疾病的藥物中的用途 | |
HUP1300025A2 (hu) | Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak elõállítására és alkalmazása | |
ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors | |
TN2014000218A1 (en) | Kinase inhibitors |